The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 President’s Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
    • Media
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 President’s Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
    • Media
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
    • Media
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
      • Summit Sponsors
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Master Class 5.0 Trial Academy 2021
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Bristol-Myers wins $752M in patent case against Gilead

Posted on December 15, 2019 by The National Trial Lawyers

Bristol-Myers Squibb Co. won a $752 million jury verdict against Gilead Sciences Inc in a U.S. patent dispute relating to technology for treating cancer.

A jury in Los Angeles awarded the damages after finding that Yescarta, a treatment sold by Gilead’s Kite Pharma unit, infringed on a patent exclusively licensed by Bristol-Myers’ Juno Therapeutics division.

The patent at issue in the lawsuit, which Juno licenses from the Memorial Sloan Kettering Cancer Center in New York, relates to CAR T-cell immunotherapy for cancer.

CAR-T therapy involves a process of removing T cells from a patient’s immune system, engineering them to better identify and attack cancer cells and infusing them back into the patient.

Read the source article at Yahoo Finance

Posted in Big Law

Comments are closed.

Recent Posts

An Abbott Subsidiary Settles False Medicare Claims and Kickbacks for $160 Million

An Abbott Subsidiary Settles False Medicare Claims and Kickbacks for $160 Million

August 4th, 2021

Alere and its now-defunct subsidiary Arriva Medical—formerly the nation’s largest supplier of mail-order diabetes[Read More...]
Tyson Foods Agrees to a $21 Million Settlement With a Group of Broiler Chicken Producers

Tyson Foods Agrees to a $21 Million Settlement With a Group of Broiler Chicken Producers

August 4th, 2021

Tyson Foods Inc. has reached a proposed agreement to pay $21 million to a group of broiler chicken producers that accused the[Read More...]
A Healthcare Provider Settles California Whistleblower Lawsuits for $37 Million

A Healthcare Provider Settles California Whistleblower Lawsuits for $37 Million

August 2nd, 2021

Southern California-based Prime Healthcare Services and two of its doctors will pay $37.5 million to settle whistleblower law[Read More...]
Zoom Settles a Privacy Lawsuit for $85 Million

Zoom Settles a Privacy Lawsuit for $85 Million

August 2nd, 2021

Zoom will pay $85 million to settle a lawsuit claiming it violated users' privacy rights, according to a preliminary settleme[Read More...]
Tesla Settles Battery Throttling Complaints for $1.5 Million

Tesla Settles Battery Throttling Complaints for $1.5 Million

July 30th, 2021

Back in 2019, Tesla pushed an over-the-air update to its Model S sedans following an incident wherein the vehicle c[Read More...]

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.